Sanjivani Paranteral [SANJIVIN] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Sanjivani Paranteral
BSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sanjivani Paranteral wins in 8 metrics, Divi's Laboratories wins in 11 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sanjivani Paranteral | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.50 | 67.57 | Sanjivani Paranteral |
| Price-to-Book Ratio | 7.12 | 10.40 | Sanjivani Paranteral |
| Debt-to-Equity Ratio | 20.42 | 0.03 | Divi's Laboratories |
| PEG Ratio | -50.71 | 2.55 | Sanjivani Paranteral |
| EV/EBITDA | 26.30 | 49.66 | Sanjivani Paranteral |
| Profit Margin (TTM) | 11.34% | 23.89% | Divi's Laboratories |
| Operating Margin (TTM) | 13.88% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | 13.88% | 25.60% | Divi's Laboratories |
| Return on Equity | 20.31% | 14.64% | Sanjivani Paranteral |
| Return on Assets (TTM) | 10.35% | 12.94% | Divi's Laboratories |
| Free Cash Flow (TTM) | $-179.46M | $2.15B | Divi's Laboratories |
| Dividend Yield | N/A | 0.91% | N/A |
| 1-Year Return | -25.39% | -5.14% | Divi's Laboratories |
| Price-to-Sales Ratio (TTM) | 3.91 | 16.13 | Sanjivani Paranteral |
| Enterprise Value | $2.78B | $1,522.01B | Divi's Laboratories |
| EV/Revenue Ratio | 3.88 | 15.77 | Sanjivani Paranteral |
| Gross Profit Margin (TTM) | 37.88% | 60.33% | Divi's Laboratories |
| Revenue per Share (TTM) | $61 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $6.60 | $86.82 | Divi's Laboratories |
| Beta (Stock Volatility) | -0.88 | 0.18 | Sanjivani Paranteral |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sanjivani Paranteral vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sanjivani Paranteral | 0.27% | -2.46% | -9.50% | 2.13% | -3.83% | -41.73% |
| Divi's Laboratories | 4.77% | 2.26% | -3.33% | -15.42% | 10.79% | -4.06% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sanjivani Paranteral | -25.39% | 348.49% | 2,289.37% | 574.09% | 240.66% | 275.44% |
| Divi's Laboratories | -5.14% | 63.08% | 80.80% | 444.71% | 1,530.25% | 8,023.95% |
News Based Sentiment: Sanjivani Paranteral vs Divi's Laboratories
Sanjivani Paranteral
News based Sentiment: POSITIVE
October was a positive month for Sanjivani Paranteral, marked by stock price increases and a notable increase in promoter holding. While shifts in other investor groups require monitoring, the overall trend suggests growing confidence in the company's prospects.
Divi's Laboratories
News based Sentiment: MIXED
Divi's Laboratories reported strong quarterly results and is strategically diversifying its revenue base, but faces operational challenges and mixed analyst sentiment. The technical indicators also present a cautious outlook, creating a complex investment narrative with both opportunities and risks.
Performance & Financial Health Analysis: Sanjivani Paranteral vs Divi's Laboratories
| Metric | SANJIVIN | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.83B | ₹1.61T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,866 | 455,187 |
| 90 Day Avg. Volume | 10,141 | 395,686 |
| Last Close | ₹223.05 | ₹6,104.50 |
| 52 Week Range | ₹203.10 - ₹396.95 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -43.81% | -13.67% |
| All-Time High | ₹396.95 (Dec 30, 2024) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -43.81% | -13.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.14% |
| Quarterly Earnings Growth | 0.01% | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.24% |
| Operating Margin (TTM) | 0.14% | 0.26% |
| Return on Equity (TTM) | 0.20% | 0.15% |
| Debt to Equity (MRQ) | 20.42 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹31.98 | ₹563.87 |
| Cash per Share (MRQ) | ₹2.04 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹35.94M | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹80.97M | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.91% |
| Last 12-Month Dividend | N/A | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Sanjivani Paranteral vs Divi's Laboratories
| Metric | SANJIVIN | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.50 | 67.57 |
| Forward P/E | N/A | 104.19 |
| PEG Ratio | -50.71 | 2.55 |
| Price to Sales (TTM) | 3.91 | 16.13 |
| Price to Book (MRQ) | 7.12 | 10.40 |
| Market Capitalization | ||
| Market Capitalization | ₹2.83B | ₹1.61T |
| Enterprise Value | ₹2.78B | ₹1.52T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.88 | 15.77 |
| Enterprise to EBITDA | 26.30 | 49.66 |
| Risk & Other Metrics | ||
| Beta | -0.88 | 0.18 |
| Book Value per Share (MRQ) | ₹31.98 | ₹563.87 |
Financial Statements Comparison: Sanjivani Paranteral vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANJIVIN | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹178.92M | ₹24.10B |
| Cost of Goods Sold | ₹111.14M | ₹9.56B |
| Gross Profit | ₹67.78M | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹24.84M | ₹6.17B |
| EBITDA | ₹26.83M | ₹8.48B |
| Pre-Tax Income | ₹23.01M | ₹7.33B |
| Income Tax | ₹5.70M | ₹1.88B |
| Net Income (Profit) | ₹17.31M | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANJIVIN | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹14.85M | ₹4.15B |
| Total Current Assets | ₹341.79M | ₹100.81B |
| Total Current Liabilities | ₹317.92M | ₹14.52B |
| Long-Term Debt | ₹52.89M | ₹20.00M |
| Total Shareholders Equity | ₹398.71M | ₹149.69B |
| Retained Earnings | ₹-427.89M | ₹134.00B |
| Property, Plant & Equipment | ₹386,420 | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANJIVIN | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANJIVIN | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 3,866 | 455,187 |
| Average Daily Volume (90 Day) | 10,141 | 395,686 |
| Shares Outstanding | 11.88M | 265.47M |
| Float Shares | 5.83M | 120.77M |
| % Held by Insiders | 0.58% | 0.52% |
| % Held by Institutions | 0.01% | 0.29% |
Dividend Analysis & Yield Comparison: Sanjivani Paranteral vs Divi's Laboratories
| Metric | SANJIVIN | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹60.00 |
| Last 12-Month Dividend Yield | N/A | 0.91% |
| 3-Year Avg Annual Dividend | N/A | ₹50.00 |
| 3-Year Avg Dividend Yield | N/A | 0.70% |
| 3-Year Total Dividends | N/A | ₹150.00 |
| Ex-Dividend Date | N/A | Jul 25, 2025 |